Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 The GLP-1 segment accounts for around 4% of the total diabetes care market in Pacific GLP-1 value in bDKK 1.6 1.4 1.2 1.0 0.8 0.6 0.4 0.2 0.0 Slide 58 Pacific GLP-1 market VictozaⓇ value market share in Pacific VictozaⓇ lixisenatide exenatide dulaglutide Share of total GLP-1 value diabetes care market share VictozaⓇ lixisenatide - exenatide - dulaglutide market 100% 5% CAGR value¹: 31.0% 80% 72% 4% 60% - 3% 40% 2% 20% 1% 0% 0% Aug 2016 Aug 2011 Aug 2016 Aug 2011 1 CAGR for 5-year period Source: IMS Monthly MAT August, 2016 value figures (DKK) changing diabetes® Source: IMS Monthly MAT August, 2016 value figures (DKK) novo nordisk

View entire presentation